Now live: Pro — the full 13F research suite for serious investorsSee pricing →
JOHNSON & JOHNSON (JNJ)

Q2 2025 · 13F-HR

JOHNSON & JOHNSON (JNJ)holdings as filed

Filed 2025-07-22 · accession 0000904454-25-000367

$334.1M
Reported value
20
Positions
2025-06-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
74366E102PTGXProtagonist Therapeutics Inc.$136.4M40.8%2,449,183CommonSHARED
G59665102MGTXMeiraGTx Holdings plc$43.9M13.1%6,641,064CommonSHARED
75383L102RAPPRapport Therapeutics, Inc.$28.6M8.55%2,498,051CommonSHARED
52490G102LEGNLegend Biotech Corporation$28.2M8.44%814,586CommonSHARED
63009J107NBTXNanobiotix S.A.$25.5M7.62%5,623,816CommonSHARED
126638105CVRXCVRx, Inc.$23.9M7.15%4,103,430CommonSHARED
74276L105PRCTProcept BioRobotics Corporation$20.4M6.10%357,939CommonSHARED
21217B100CTNMContineum Therapeutics Inc.$8.1M2.43%1,979,173CommonSHARED
98401F105XNCRXencor, Inc.$6.1M1.82%748,062CommonSHARED
04280A100ARWRArrowhead Pharmaceuticals, Inc.$4.0M1.19%247,598CommonSHARED
31189P102FATEFate Therapeutics, Inc.$3.5M1.05%3,379,064CommonSHARED
640979100NMRANeumora Therapeutics, Inc.$1.4M0.42%1,849,445CommonSHARED
75120L100Rallybio Corporation$1.2M0.36%3,636,363CommonSHARED
929033108Vor Biopharma, Inc.$1.1M0.34%1,074,658CommonSHARED
M70700105NNOXNano-X Imaging Ltd.$830,7960.25%158,852CommonSHARED
34385P108LABStandard BioTools Inc$371,2410.11%311,967CommonSHARED
55083R104Lyell Immunopharma Inc.$368,0150.11%41,165CommonSHARED
007002108TORCEURAdicet Bio, Inc.$228,0140.07%364,472CommonSHARED
09090D103BiomX Inc.$42,6210.01%96,866CommonSHARED
81727U105SENS1GBPSenseonics Holdings, Inc.$26,9880.01%54,621CommonSHARED

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.